7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Using Species a Rotavirus Reverse Genetics to Engineer Chimeric Viruses Expressing SARS-CoV-2 Spike Epitopes

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          Species A rotavirus (RVA) vaccines based on live attenuated viruses are used worldwide in humans. The recent establishment of a reverse genetics system for rotoviruses (RVs) has opened the possibility of engineering chimeric viruses expressing heterologous peptides from other viral or microbial species in order to develop polyvalent vaccines. We tested the feasibility of this concept by two approaches. First, we inserted short SARS-CoV-2 spike peptides into the hypervariable region of the simian RV SA11 strain viral protein (VP) 4. Second, we fused the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, or the shorter receptor binding motif (RBM) nested within the RBD, to the C terminus of nonstructural protein (NSP) 3 of the bovine RV RF strain, with or without an intervening Thosea asigna virus 2A (T2A) peptide. Mutating the hypervariable region of SA11 VP4 impeded viral replication, and for these mutants, no cross-reactivity with spike antibodies was detected. To rescue NSP3 mutants, we established a plasmid-based reverse genetics system for the bovine RV RF strain. Except for the RBD mutant that demonstrated a rescue defect, all NSP3 mutants delivered endpoint infectivity titers and exhibited replication kinetics comparable to that of the wild-type virus. In ELISAs, cell lysates of an NSP3 mutant expressing the RBD peptide showed cross-reactivity with a SARS-CoV-2 RBD antibody. 3D bovine gut enteroids were susceptible to infection by all NSP3 mutants, but cross-reactivity with SARS-CoV-2 RBD antibody was only detected for the RBM mutant. The tolerance of large SARS-CoV-2 peptide insertions at the C terminus of NSP3 in the presence of T2A element highlights the potential of this approach for the development of vaccine vectors targeting multiple enteric pathogens simultaneously.

          IMPORTANCE We explored the use of rotaviruses (RVs) to express heterologous peptides, using SARS-CoV-2 as an example. Small SARS-CoV-2 peptide insertions (<34 amino acids) into the hypervariable region of the viral protein 4 (VP4) of RV SA11 strain resulted in reduced viral titer and replication, demonstrating a limited tolerance for peptide insertions at this site. To test the RV RF strain for its tolerance for peptide insertions, we constructed a reverse genetics system. NSP3 was C-terminally tagged with SARS-CoV-2 spike peptides of up to 193 amino acids in length. With a T2A-separated 193 amino acid tag on NSP3, there was no significant effect on the viral rescue efficiency, endpoint titer, and replication kinetics. Tagged NSP3 elicited cross-reactivity with SARS-CoV-2 spike antibodies in ELISA. We highlight the potential for development of RV vaccine vectors targeting multiple enteric pathogens simultaneously.

          Related collections

          Most cited references113

          • Record: found
          • Abstract: found
          • Article: not found

          Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

          A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from December 2019 that quickly spread nationwide and to other countries around the world1-3. Here, to better understand the initial step of infection at an atomic level, we determined the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2. The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor4. Structural analysis identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD. Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses1-3,5. The epitopes of two SARS-CoV antibodies that target the RBD are also analysed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Analyzing real-time PCR data by the comparative CT method

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              SARS-CoV-2 vaccines in development

              Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                J Virol
                J Virol
                JVI
                Journal of Virology
                American Society for Microbiology (1752 N St., N.W., Washington, DC )
                0022-538X
                1098-5514
                27 June 2022
                July 2022
                27 June 2022
                : 96
                : 14
                : e00488-22
                Affiliations
                [a ] Infection and Immunity Division, Roslin Institute, University of Edinburghgrid.4305.2, , Easter Bush Campus, Midlothian, United Kingdom
                [b ] Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom
                [c ] Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
                Loyola University Chicago
                Author notes

                The authors declare no conflict of interest.

                Author information
                https://orcid.org/0000-0002-0872-9440
                https://orcid.org/0000-0002-4473-6373
                Article
                00488-22 jvi.00488-22
                10.1128/jvi.00488-22
                9327695
                35758692
                cf026a58-8822-4a5a-a9fc-f855b5ae55dc
                Copyright © 2022 American Society for Microbiology.

                All Rights Reserved.

                This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 22 March 2022
                : 31 May 2022
                Page count
                Figures: 7, Tables: 4, Equations: 0, References: 113, Pages: 25, Words: 15990
                Funding
                Funded by: UKRI | Biotechnology and Biological Sciences Research Council (BBSRC), FundRef https://doi.org/10.13039/501100000268;
                Award ID: BB/P013740/1
                Award Recipient :
                Funded by: UKRI | Biotechnology and Biological Sciences Research Council (BBSRC), FundRef https://doi.org/10.13039/501100000268;
                Award ID: BB/P013740/1
                Award Recipient :
                Funded by: Wellcome Trust (WT), FundRef https://doi.org/10.13039/100010269;
                Award ID: 211222_Z_18_Z
                Award Recipient :
                Funded by: Wellcome Trust (WT), FundRef https://doi.org/10.13039/100010269;
                Award ID: 211138/Z/18/Z
                Award Recipient :
                Categories
                Cellular Response to Infection
                virology, Virology
                Custom metadata
                July 2022

                Microbiology & Virology
                rotavirus,nsp3,vp4,reverse genetics
                Microbiology & Virology
                rotavirus, nsp3, vp4, reverse genetics

                Comments

                Comment on this article